相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Redefining nonmeasurable multiple myeloma using mass spectrometry
Hannah Giles et al.
BLOOD (2022)
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
Luciano J. Costa et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)
Angela Dispenzieri et al.
BLOOD CANCER JOURNAL (2022)
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma
Noemi Puig et al.
BLOOD ADVANCES (2022)
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
Jesus San-Miguel et al.
BLOOD (2022)
Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine
Martina Zatopkova et al.
BLOOD ADVANCES (2022)
A Cost Impact Analysis of clonoSEQ® as a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic Compared to No MRD Testing in Multiple Myeloma in Germany
Stefan Walzer et al.
ONCOLOGY AND THERAPY (2021)
High-Throughput Therapeutic Antibody Interference-Free High-Resolution Mass Spectrometry Assay for Monitoring M-Proteins in Multiple Myeloma
Rasa Santockyte et al.
ANALYTICAL CHEMISTRY (2021)
Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma
Jithma P. Abeykoon et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial
Noemi Puig et al.
BLOOD (2021)
Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment
Hannah Victoria Giles et al.
BLOOD (2021)
High Prevalence of Monoclonal Gammopathy in a Population at Risk: The First Results of the Promise Study
Habib El-Khoury et al.
BLOOD (2021)
Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma
Olwen Westerland et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Clearing drug interferences in myeloma treatment using mass spectrometry
Mindy C. Kohlhagen et al.
CLINICAL BIOCHEMISTRY (2021)
Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for Minimal Residual Disease Monitoring in Multiple Myeloma
Pieter Langerhorst et al.
CLINICAL CHEMISTRY (2021)
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report
David L. Murray et al.
BLOOD CANCER JOURNAL (2021)
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation
Benjamin A. Derman et al.
BLOOD CANCER JOURNAL (2021)
MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients
Patrick W. Mellors et al.
BLOOD CANCER JOURNAL (2021)
Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy
Marion Eveillard et al.
CLINICA CHIMICA ACTA (2021)
A Personalized Mass Spectrometry-Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM)
Mariya Liyasova et al.
CLINICAL CANCER RESEARCH (2021)
Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference
Somayya Noori et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2021)
Imaging in myeloma: a Royal College of Radiologists national survey of current imaging practice
O. Westerland et al.
CLINICAL RADIOLOGY (2021)
MASS-FIX versus standard methods to predict for PFS and OS among multiple myeloma patients participating on the STAMINA trial.
Angela Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Analysis of minimal residual disease in bone marrow by NGF and in peripheral blood by mass spectrometry in newly diagnosed multiple myeloma patients enrolled in the GEM2012MENOS65 clinical trial.
Noemi Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
Stefania Oliva et al.
BLOOD CANCER JOURNAL (2021)
Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma
David Foureau et al.
CANCER MEDICINE (2021)
Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma
Christina Messiou et al.
RADIOLOGY-IMAGING CANCER (2021)
Multiple myeloma: Detection of free monoclonal light chains by modified immunofixation electrophoresis with antisera against free light chains
Dorian Wilhite et al.
PRACTICAL LABORATORY MEDICINE (2021)
Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis
Eli Muchtar et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2020)
Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis
Herve Avet-Loiseau et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis
Surbhi Sidana et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis
Angela Dispenzieri et al.
BLOOD CANCER JOURNAL (2020)
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Peter M. Voorhees et al.
BLOOD (2020)
Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma patients: Comparison between the standard and IMWG MRD criteria and QIP-MS including FLC (QIP-FLC-MS).
Noemí Puíg et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Mass Spectrometry-Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma
Carlo O. Martins et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2020)
N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression
Angela Dispenzieri et al.
LEUKEMIA (2020)
The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements
Maria-Teresa Cedena et al.
PLOS ONE (2020)
Cost-Effectiveness of Implementing Clonoseq NGS-MRD Testing Using the Emory MRD Decision Protocol in Multiple Myeloma
Josh J. Carlson et al.
BLOOD (2020)
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Alejandro Medina et al.
BLOOD CANCER JOURNAL (2020)
Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients
Sanjay Kumar et al.
LEUKEMIA (2019)
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
Habte Yimer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Low hexokinase-2 expression-associated false-negative 18F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma
Yoshiaki Abe et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy
Marcella A. Tschautscher et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma
Rafael Alonso et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins
Lauren M. Moore et al.
CLINICA CHIMICA ACTA (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Quantitative Immunoprecipitation Free Light Chain Mass Spectrometry (QIP-FLC-MS) Simplifies Monoclonal Protein Assessment and Provides Added Clinical Value in Systemic AL Amyloidosis
Faye Amelia Sharpley et al.
BLOOD (2019)
A Longitudinal Evaluation of Euroflow and Combined Quantitative Immunoprecipitation (QIP) and Free Light Chain (FLC) Mass Spectometry (MS) in Functional High Risk Multiple Myeloma
Andrew Spencer et al.
BLOOD (2019)
Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment
Noemi Puig et al.
BLOOD (2019)
Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
L. Rasche et al.
LEUKEMIA (2019)
Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement
David Murray et al.
BLOOD CANCER JOURNAL (2019)
Correlation Between Uptake of 18F-FDG During PET/CT and Ki-67 Expression in Patients Newly Diagnosed With Multiple Myeloma Having Extramedullary Involvement
Qian Li et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2019)
Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay
Katie L. Thoren et al.
JOURNAL OF APPLIED LABORATORY MEDICINE (2019)
A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference
John R. Mills et al.
BLOOD (2018)
Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy
C. Amos Clark et al.
BONE MARROW TRANSPLANTATION (2018)
Diagnostic performance of F-18-FDG PET/CT and whole-body MRI before and early after treatment of multiple myeloma: a prospective comparative study
Mohammad Abd Alkhalik Basha et al.
JAPANESE JOURNAL OF RADIOLOGY (2018)
Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal Antibodies
Marina Zajec et al.
JOURNAL OF PROTEOME RESEARCH (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Diagnostic performance of F-18-FDG PET/CT and whole-body MRI before and early after treatment of multiple myeloma: a prospective comparative study
Mohammad Abd Alkhalik Basha et al.
JAPANESE JOURNAL OF RADIOLOGY (2018)
Longitudinal Flow Cytometry Identified Minimal Residual Disease (MRD) Evolution Patterns for Predicting the Prognosis of Patients with Transplant-Eligible Multiple Myeloma
Jingli Gu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma
Tilmann Bochtler et al.
BLOOD ADVANCES (2018)
Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study
Philippe Moreau et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
J. Flores-Montero et al.
LEUKEMIA (2017)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma
J. R. Mills et al.
BLOOD CANCER JOURNAL (2017)
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma A Meta-analysis
Nikhil C. Munshi et al.
JAMA ONCOLOGY (2017)
The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic
Paolo Milani et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration
H. Robert Bergen et al.
CLINICAL CHEMISTRY (2016)
Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry
John R. Mills et al.
CLINICAL CHEMISTRY (2016)
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis
Giovanni Palladini et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Clinical course and prognosis of non-secretory multiple myeloma
Sagar S. Chawla et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Detecting monoclonal immunoglobulins in human serum using mass spectrometry
John R. Mills et al.
METHODS (2015)
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
Joaquin Martinez-Lopez et al.
BLOOD (2014)
Using Mass Spectrometry to Monitor Monoclonal Immunoglobulins in Patients with a Monoclonal Gammopathy
David R. Barnidge et al.
JOURNAL OF PROTEOME RESEARCH (2014)
Non-Producing Multiple Myeloma (MM) Is a Distinct Subset Of Non-Secretory MM Characterized By High Cyclin D1 Expression and Decreased Progression Free Survival
Xenofon Papanikolaou et al.
BLOOD (2013)
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents
Saad Z. Usmani et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
Giovanni Palladini et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
R. L. Comenzo et al.
LEUKEMIA (2012)
Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients
M. Varettoni et al.
ANNALS OF ONCOLOGY (2010)
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study
Angela Dispenzieri et al.
LANCET (2010)
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
A. Dispenzieri et al.
LEUKEMIA (2009)
Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure
Colin A Hutchison et al.
BMC Nephrology (2008)
New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells
Ernesto Perez-Persona et al.
BLOOD (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants
H Avet-Loiseau et al.
BLOOD (2003)
Glycosylation of immunoglobulin light chains associated with amyloidosis
LA Omtvedt et al.
AMYLOID-INTERNATIONAL JOURNAL OF EXPERIMENTAL AND CLINICAL INVESTIGATION (2000)
分享论文
